Importance of Rebates and Future of Biosimilar Market | AMCP Nexus 2024
An optimistic outlook on the future of the biosimilar market driving down pharmaceutical drug spend.
In this discussion, Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca, highlights the critical role of rebates in maintaining affordable health plan premiums and accessibility of specialty drugs.
“A lot of people say that the biosimilar space is at risk - I don't believe that,” Gonzalez said. “I think it will continue to be one of the main drivers of lowering our overall pharmaceutical drug spend over the next five to 10 years.”
Abarca is a health IT company and pharmacy benefit manager. Gonzalez co-led the session, ‘Are Patients Getting a Fair Share of the Value of Biosimilars?’ today at AMCP Nexus, held at the MGM Grand in Las Vegas.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Is Journavx a Step Forward In Pain Management or a Repeat of Past Mistakes?
March 25th 2025In a Q&A with Josef Witt-Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares the potential benefits and risks of the alternative non-opioid pain medication, expressing that while it could help cut down on opioid use, its long-term impact is unclear.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
